PT91420B - Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus - Google Patents

Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus Download PDF

Info

Publication number: PT91420B
Authority: PT; Portugal
Prior art keywords: insulin; arg; core core; formula; treatment
Prior art date: 1988-08-13

Application number

PT91420A

Other languages

English (en)

Portuguese (pt)

Other versions

PT91420A (pt

Inventor

Michael Dorschug

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-13

Filing date

1989-08-10

Publication date

1995-05-04

1989-08-10 Application filed by Hoechst Ag filed Critical Hoechst Ag

1990-03-08 Publication of PT91420A publication Critical patent/PT91420A/pt

1995-05-04 Publication of PT91420B publication Critical patent/PT91420B/pt

Links

238000000034 method Methods 0.000 title claims description 11
239000008194 pharmaceutical composition Substances 0.000 title abstract description 9
206010012601 diabetes mellitus Diseases 0.000 title abstract description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 37
102000004877 Insulin Human genes 0.000 claims abstract description 14
108090001061 Insulin Proteins 0.000 claims abstract description 14
150000001875 compounds Chemical class 0.000 claims description 18
229940125396 insulin Drugs 0.000 claims description 14
101000976075 Homo sapiens Insulin Proteins 0.000 claims description 3
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 3
LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims 1
108010005991 Pork Regular Insulin Proteins 0.000 claims 1
125000002252 acyl group Chemical group 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
239000012948 isocyanate Substances 0.000 claims 1
150000002513 isocyanates Chemical class 0.000 claims 1
239000002088 nanocapsule Substances 0.000 claims 1
239000011701 zinc Substances 0.000 abstract description 7
239000000203 mixture Substances 0.000 abstract description 6
150000003839 salts Chemical class 0.000 abstract description 6
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 5
229910052725 zinc Inorganic materials 0.000 abstract description 5
239000004026 insulin derivative Substances 0.000 abstract description 4
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract description 2
230000002349 favourable effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
238000002360 preparation method Methods 0.000 description 7
239000002253 acid Substances 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
125000003282 alkyl amino group Chemical group 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008103 glucose Substances 0.000 description 3
101150035983 str1 gene Proteins 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
150000003751 zinc Chemical class 0.000 description 2
-1 -isopropyl ester Chemical class 0.000 description 1
LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
241000023308 Acca Species 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
240000003023 Cosmos bipinnatus Species 0.000 description 1
235000005956 Cosmos caudatus Nutrition 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102000047352 Esterase-like Human genes 0.000 description 1
108700037229 Esterase-like Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102100021496 Insulin-degrading enzyme Human genes 0.000 description 1
108090000828 Insulysin Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241000287118 Parus Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
238000006254 arylation reaction Methods 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
230000036407 pain Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
150000008442 polyphenolic compounds Chemical class 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT91420A 1988-08-13 1989-08-10 Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus PT91420B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3827533A DE3827533A1 (de)	1988-08-13	1988-08-13	Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Publications (2)

Publication Number	Publication Date
PT91420A PT91420A (pt)	1990-03-08
PT91420B true PT91420B (pt)	1995-05-04

Family

ID=6360797

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT91420A PT91420B (pt)	1988-08-13	1989-08-10	Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus

Country Status (18)

Country	Link
US (1)	US5177058A (2)
EP (1)	EP0357978B1 (2)
JP (1)	JPH02101022A (2)
KR (1)	KR900002801A (2)
AT (1)	ATE75945T1 (2)
AU (1)	AU621648B2 (2)
CA (1)	CA1332354C (2)
DE (2)	DE3827533A1 (2)
DK (1)	DK395689A (2)
ES (1)	ES2039773T3 (2)
FI (1)	FI95202C (2)
GR (1)	GR3005326T3 (2)
HU (1)	HU203670B (2)
IE (1)	IE61266B1 (2)
NO (1)	NO178914C (2)
NZ (1)	NZ230280A (2)
PT (1)	PT91420B (2)
ZA (1)	ZA896149B (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875589B1 (en) *	1988-06-23	2005-04-05	Hoechst Aktiengesellschaft	Mini-proinsulin, its preparation and use
DE4024434A1 (de) *	1990-08-01	1992-02-13	Fresenius Ag	Vorrichtung zur ultrafiltrationskontrolle bzw. ultrafiltrationsregelung bei blutreinigungsverfahren
NZ250844A (en) *	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US5534488A (en) *	1993-08-13	1996-07-09	Eli Lilly And Company	Insulin formulation
YU18596A (sh) *	1995-03-31	1998-07-10	Eli Lilly And Company	Analogne formulacije monomernog insulina
DK0821006T3 (da) *	1996-07-26	2004-08-16	Aventis Pharma Gmbh	Insulinderivater med öget zinkbinding
EP1044016B1 (en) *	1998-01-09	2005-03-16	Novo Nordisk A/S	Stabilised insulin compositions
DE19825447A1 (de)	1998-06-06	1999-12-09	Hoechst Marion Roussel De Gmbh	Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
PL374949A1 (en) *	2001-12-20	2005-11-14	Eli Lilly And Company	Insulin molecule having protracted time action
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US20060217290A1 (en) *	2003-04-29	2006-09-28	Kohn Wayne D	Insulin analogs having protracted time action
MXPA06001283A (es) *	2003-08-05	2006-04-11	Novo Nordisk As	Derivados de insulina novedosos.
BRPI0513508B1 (pt)	2004-07-19	2021-06-01	Biocon Limited	Conjugados de insulina-oligômero, formulações e usos desses
JP4808785B2 (ja)	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	インスリン組成物および組成物の製造方法
US9034818B2 (en) *	2007-06-13	2015-05-19	Novo Nordisk A/S	Pharmaceutical formulations comprising an insulin derivative
JP5868594B2 (ja) *	2007-10-16	2016-02-24	バイオコン・リミテッドＢｉｏｃｏｎＬｉｍｉｔｅｄ	経口投与可能な固形医薬組成物及びそのプロセス
CN102256618A (zh)	2008-10-17	2011-11-23	赛诺菲-安万特德国有限公司	胰岛素和glp-1激动剂的组合
AU2009309623B9 (en) *	2008-10-30	2014-10-02	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
PL2451437T3 (pl)	2009-07-06	2017-05-31	Sanofi-Aventis Deutschland Gmbh	Wodne preparaty insuliny zawierające metioninę
NZ599847A (en)	2009-11-13	2013-09-27	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr)	2009-11-13	2018-07-23	Sanofi Aventis Deutschland	Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
WO2012028172A1 (en)	2010-08-30	2012-03-08	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
PE20171622A1 (es)	2014-12-12	2017-11-02	Sanofi Aventis Deutschland	Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2143591A (en) *	1936-09-26	1939-01-10	Univ Alberta	Therapeutic preparation and process of making and using it
US2354211A (en) *	1940-07-02	1944-07-25	Burroughs Wellcome Co	Insulin preparation
DOP1982004086A (es) *	1981-08-27	1988-03-22	Lilly Co Eli	Formula farmaceutica que comprende insulina humana y proinsulina humana
DE3326473A1 (de) *	1983-07-22	1985-01-31	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) *	1983-07-22	1985-02-14	Hoechst Ag, 6230 Frankfurt	Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) *	1983-09-17	1985-04-25	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3334407A1 (de) *	1983-09-23	1985-04-04	Hoechst Ag, 6230 Frankfurt	In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DK113585D0 (da) *	1985-03-12	1985-03-12	Novo Industri As	Nye peptider
DK347086D0 (da) *	1986-07-21	1986-07-21	Novo Industri As	Novel peptides

1988
- 1988-08-13 DE DE3827533A patent/DE3827533A1/de not_active Withdrawn
1989
- 1989-08-08 ES ES89114617T patent/ES2039773T3/es not_active Expired - Lifetime
- 1989-08-08 EP EP89114617A patent/EP0357978B1/de not_active Expired - Lifetime
- 1989-08-08 AT AT89114617T patent/ATE75945T1/de not_active IP Right Cessation
- 1989-08-08 DE DE8989114617T patent/DE58901401D1/de not_active Expired - Lifetime
- 1989-08-10 FI FI893783A patent/FI95202C/fi not_active IP Right Cessation
- 1989-08-10 PT PT91420A patent/PT91420B/pt not_active IP Right Cessation
- 1989-08-11 HU HU894148A patent/HU203670B/hu unknown
- 1989-08-11 AU AU39514/89A patent/AU621648B2/en not_active Expired
- 1989-08-11 CA CA000608115A patent/CA1332354C/en not_active Expired - Lifetime
- 1989-08-11 US US07/392,559 patent/US5177058A/en not_active Expired - Lifetime
- 1989-08-11 IE IE259489A patent/IE61266B1/en not_active IP Right Cessation
- 1989-08-11 ZA ZA896149A patent/ZA896149B/xx unknown
- 1989-08-11 KR KR1019890011430A patent/KR900002801A/ko not_active Withdrawn
- 1989-08-11 NO NO893239A patent/NO178914C/no unknown
- 1989-08-11 DK DK395689A patent/DK395689A/da not_active Application Discontinuation
- 1989-08-11 NZ NZ230280A patent/NZ230280A/xx unknown
- 1989-08-11 JP JP1207057A patent/JPH02101022A/ja active Pending
1992
- 1992-07-31 GR GR920401367T patent/GR3005326T3/el unknown

Also Published As

Publication number	Publication date
ZA896149B (en)	1990-04-25
DK395689A (da)	1990-02-14
IE892594L (en)	1990-02-13
DE58901401D1 (de)	1992-06-17
NO893239D0 (no)	1989-08-11
FI95202C (fi)	1996-01-10
EP0357978B1 (de)	1992-05-13
FI95202B (fi)	1995-09-29
AU621648B2 (en)	1992-03-19
HUT50443A (en)	1990-02-28
GR3005326T3 (2)	1993-05-24
US5177058A (en)	1993-01-05
IE61266B1 (en)	1994-10-19
JPH02101022A (ja)	1990-04-12
NO178914B (no)	1996-03-25
ES2039773T3 (es)	1996-07-16
EP0357978A1 (de)	1990-03-14
PT91420A (pt)	1990-03-08
DK395689D0 (da)	1989-08-11
KR900002801A (ko)	1990-03-23
HU203670B (en)	1991-09-30
NO178914C (no)	1996-07-03
FI893783A0 (fi)	1989-08-10
AU3951489A (en)	1990-02-15
CA1332354C (en)	1994-10-11
FI893783L (fi)	1990-02-14
NZ230280A (en)	1991-09-25
ATE75945T1 (de)	1992-05-15
NO893239L (no)	1990-02-14
DE3827533A1 (de)	1990-02-15

Legal Events

Date

Code

Title

Description

1995-05-04

FG3A

Patent granted, date of granting

Effective date: 19941007

2009-10-15

MM4A

Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20091007

Publication	Publication Date	Title
PT91420B (pt)	1995-05-04	Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus
KR930000861B1 (ko)	1993-02-08	오메프라졸 직장투여 조성물
AU712927B2 (en)	1999-11-18	Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
US5080893A (en)	1992-01-14	Method for preventing surgical adhesions using a dilute solution of polymer
JP2694166B2 (ja)	1997-12-24	ゲル形成液体担体組成物
US6464970B1 (en)	2002-10-15	Method and composition for preventing surgical adhesions
US5350573A (en)	1994-09-27	Method and composition for preventing surgical adhesions
JP3779200B2 (ja)	2006-05-24	ヒアルロン酸及び／又はその塩の水溶液の安定化組成物
US6858673B1 (en)	2005-02-22	Composition for hydrogel, hydrogel and use thereof
DE60034568D1 (de)	2007-06-06	Zusammensetzungen mit verzögerter freigabe, verfahren zu deren herstellung und verwendung
EP1203784B1 (en)	2008-12-10	Polymer, in vivo degradable material, and use
JP2006182750A (ja)	2006-07-13	凍結乾燥化粧品およびその製造方法
EP0319964B1 (en)	1992-03-18	Film-formation-type antifungal preparation
CA1341093C (en)	2000-09-05	Method and composition for preventing surgical adhesions
SE451666B (sv)	1987-10-26	Stabil bensoylperoxidkomposition
EP0315401A3 (en)	1991-01-16	Xanthine derivatives and their preparation and pharmaceutical formulation
WO2021033898A1 (ko)	2021-02-25	침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물
NO823420L (no)	1984-04-16	Sulfonerte vinylaromatiske homopolymerer og kopolymerer som middel for hindring av plaque paa tenner
DK166993B1 (da)	1993-08-16	Anthelmintisk vandigt gelpraeparat til oral indgift, isaer af aelevamisolae og aetetremisolae, og fremgangsmaade til dets fremstilling.
TR2023015684A2 (tr)	2024-01-22	Akne Tedavisi için Azelaik Asit-Siklodekstrin Kompleks Bazlı Hidrojel Formülasyonları
AU628114B2 (en)	1992-09-10	Pharmaceutical composition for ophthalmic use comprising a water soluble acid addition salt of ibopamine
JPS6281319A (ja)	1987-04-14	前眼部手術用の前房注入剤
Brown et al.	1985	Effects of selective channel blocking agents on contractions and action potentials in K+‐depolarized guinea‐pig atria
KR100214714B1 (ko)	1999-08-02	신규한 국소마취제 함유 겔제제
WO2014090889A1 (en)	2014-06-19	Oral solutions comprising folic acid